We report the case of a 50-year-old patient diagnosed with breast cancer with lymph node, lymph node, pulmonary and hepatic secondaryisms. After receiving a first line chemotherapy containing taxanes, pertuzumab and trastuzumab, the patient developed asymptomatic brain metastases. She is therefore treated with panencephalic radiotherapy and second line treatment with trastuzumab emtansine. Further to systemic and cerebral disease progression, the patient is treated with capecitabine and lapatinib. This treatment lasted approximately 6 months with sustained efficacy on secondary lesions and an excellent tolerance profile (Oncology
The incidence of brain metastases (BMs) is apparently rising in patients with advanced breast cancer...
This is a case report of a 40-year-old woman who, after conservative breast cancer treatment, develo...
L’iperespressione/amplificazione del gene HER2 si verifica in circa il 15-20% dei carcinomi della ma...
HER2 overexpression occurs in about 15-20% of breast cancer cases and is associated with rapid tumor...
S We present the case of a patient affected by HER2-positive breast carcinoma, relapsed at supracla...
Overexpression of the human epidermal growth factor receptor (HER2) oncoprotein in breast cancer pat...
Lapatinib is a small molecule that reversibly inhibits the tyrosine kinase activity of EGFR and HER2...
We report the case of a young, 36-year-old patient diagnosed with multifocal breast carcinoma, under...
Lapatinib is a small molecule and a reversible inhibitor of HER2, which has shown to be effective on...
Lapatinib is an intracellular tyrosine kinase inhibitor of EGFR (ErbB1) and HER2 (ErbB2) receptors, ...
La sovraespressione dell'oncoproteina HER2 (human epidermal growth factor receptor 2), spesso sosten...
Aim: HER2 receptor is a molecular target for breast cancer therapy. Two drugs acts against this rece...
Il carcinoma della mammella è per frequenza il primo tra i tumori nel sesso femminile, rappresentand...
L’Human Epidermal Growth Factor Receptor 2 (HER2) è un importante recettore per fattori di crescita ...
Il carcinoma della mammella di tipo HER2 positivo costituisce circa il 20% della casistica ed in pas...
The incidence of brain metastases (BMs) is apparently rising in patients with advanced breast cancer...
This is a case report of a 40-year-old woman who, after conservative breast cancer treatment, develo...
L’iperespressione/amplificazione del gene HER2 si verifica in circa il 15-20% dei carcinomi della ma...
HER2 overexpression occurs in about 15-20% of breast cancer cases and is associated with rapid tumor...
S We present the case of a patient affected by HER2-positive breast carcinoma, relapsed at supracla...
Overexpression of the human epidermal growth factor receptor (HER2) oncoprotein in breast cancer pat...
Lapatinib is a small molecule that reversibly inhibits the tyrosine kinase activity of EGFR and HER2...
We report the case of a young, 36-year-old patient diagnosed with multifocal breast carcinoma, under...
Lapatinib is a small molecule and a reversible inhibitor of HER2, which has shown to be effective on...
Lapatinib is an intracellular tyrosine kinase inhibitor of EGFR (ErbB1) and HER2 (ErbB2) receptors, ...
La sovraespressione dell'oncoproteina HER2 (human epidermal growth factor receptor 2), spesso sosten...
Aim: HER2 receptor is a molecular target for breast cancer therapy. Two drugs acts against this rece...
Il carcinoma della mammella è per frequenza il primo tra i tumori nel sesso femminile, rappresentand...
L’Human Epidermal Growth Factor Receptor 2 (HER2) è un importante recettore per fattori di crescita ...
Il carcinoma della mammella di tipo HER2 positivo costituisce circa il 20% della casistica ed in pas...
The incidence of brain metastases (BMs) is apparently rising in patients with advanced breast cancer...
This is a case report of a 40-year-old woman who, after conservative breast cancer treatment, develo...
L’iperespressione/amplificazione del gene HER2 si verifica in circa il 15-20% dei carcinomi della ma...